我要投票 承慶堂在医疗器械行业中的票数:104
· 外 推 电 报 ·
2025-02-23 19:26:21 星期日

【承慶堂是哪个国家的品牌?】

承慶堂是什么牌子?「承慶堂」是 安徽承庆堂国药股份有限公司 旗下著名品牌。该品牌发源于安徽省亳州市,由创始人李整风在2012-01-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力承慶堂品牌出海!通过在本页面挂载承慶堂品牌的产品链接和联系邮箱,可以提高承慶堂产品曝光!跨境电商爆单神器,目前只要100元/年哦~

安徽承庆堂国药股份有限公司(原亳州正丰医药有限责任公司)是于2001年投资建设的集医疗器械生产与销售一体化公司,是一家集医疗器械的技术研发、技术咨询为产业核心,采用国际OEM模式,以掌控知识产权为入手、以医药科研为主的企业,主打“承庆堂”骨病系列外用贴剂产品,以疗效显著、品质稳定深得广大骨科医院及消费者的认可和好评。公司在医药行业经过短短几年的发展历程,依靠自身产品的绝对疗效已形成了骨病系列外用贴剂的知名品牌。“品质决定品牌”,创造骨病系列外用贴剂的医药品牌是正丰医药人孜孜不倦和执着追求的目标。

公司拥有一支团结、创新、奋进的技术研发队伍,在公司全体员工的共同努力下,企业坚持走专业化道路,形成了“材料来源基地化,检测手段科学化,制作工艺规范化,贴剂质量标准化,设计包装规格化”的“五化”管理模式,产品“选料上乘,工艺考究,疗效显著”。提升了“承庆堂”品牌的知名度和美誉度。始终坚持靠诚信打造自身品牌、靠质量占领市场先机、靠服务赢得行业机遇、靠管理推动企业发展的理念,在严峻的医药行业形势下,注重发挥自身优势,做大做强主营业务,我们坚信“一生只做一件事”,在同行业内取得了骄人的业绩,公司在发展过程中,得到了各级领导和相关职能管理部门的正确指引和极大的关怀,在广大医药流通企业和商业客户的支持下,在全国药业行业中,凭借自身实力和产品品质,铸就了企业在医药行业及广大骨科医院的巩固地位。目前,公司已与国内多家骨科医院和众多客户建立了紧密、稳固的合作关系,形成了强大的销售网络和品牌优势。公司也一直专注于现代企业制度的建设,目前已经在企业的产权结构、运营模式、管理制度、业务流程上达到了一定水平,并形成了自己的特色。

公司自2007年就尝试运作终端销售模式,即在有条件的骨科医院设立精品药房,截至目前已在国内多家骨科医院建立了上百家精品药房,此模式的成功运作,有利于实现名企、名院、名医、名品的优化组合,扩大医疗机构的服务范围,为患者提供疗效显著、价格合理的诚信医疗服务。我们诚邀各大骨科医院垂询来访,共筑合作平台,实现医药携手共赢发展。

在如今医药行业新的竞争和挑战中,我们将拥有更加广阔的医药市场。“海内存知己,天涯若比邻”,公司愿与全国各大骨科医院、连锁药房及各界的朋友真诚合作、共创辉煌!



英文翻译:Anhui chengqingtang State Pharmaceutical Co., Ltd. (formerly Bozhou Zhengfeng Pharmaceutical Co., Ltd.) is an integrated production and sales company of medical devices invested and constructed in 2001. It is an enterprise that focuses on technical research and development and technical consultation of medical devices, adopts the international OEM mode, controls intellectual property rights and focuses on medical research, and focuses on "chengqingtang" osteopathy A series of external patch products, with remarkable curative effect and stable quality, have won the recognition and praise of orthopedic hospitals and consumers. After just a few years of development in the pharmaceutical industry, relying on the absolute efficacy of its own products, the company has formed a well-known brand of bone disease series external patches. "Quality determines the brand" and creating a brand of external use of orthopedic patches is the goal of Zhengfeng pharmaceutical people. The company has a united, innovative and progressive technology research and development team. With the joint efforts of all employees, the company adheres to the path of specialization, forming a "five chemical" management mode of "base of material sources, scientific detection means, standardized production process, standardized paste quality, standardized design and packaging". The product "selects the best materials, exquisite technology, and curative effect" Remarkable. It has improved the popularity and reputation of chengqingtang brand. We always adhere to the concept of building our own brand by integrity, seizing the market opportunity by quality, winning industry opportunities by service, and promoting enterprise development by management. Under the severe situation of the pharmaceutical industry, we pay attention to giving full play to our own advantages and making our main business bigger and stronger. We firmly believe that "only one thing in life" has made remarkable achievements in the same industry. In the process of development, the company has obtained With the correct guidance and great care of leaders at all levels and relevant functional management departments, supported by the majority of pharmaceutical circulation enterprises and commercial customers, and with its own strength and product quality in the national pharmaceutical industry, the company has established a firm position in the pharmaceutical industry and the majority of orthopedic hospitals. At present, the company has established close and stable cooperative relations with many orthopedic hospitals and customers in China, forming a strong sales network and brand advantages. The company has also been focusing on the construction of modern enterprise system. At present, it has reached a certain level in the property right structure, operation mode, management system and business process of the enterprise, and has formed its own characteristics. Since 2007, the company has tried to operate terminal sales mode, that is, to set up boutique pharmacies in conditional orthopedic hospitals. Up to now, hundreds of boutique pharmacies have been set up in many orthopedic hospitals in China. The successful operation of this mode is conducive to the realization of the optimized combination of famous enterprises, famous hospitals, famous doctors and famous products, the expansion of the service scope of medical institutions, and the provision of significant curative effect and reasonable price for patients The integrity of medical services. We sincerely invite all orthopedic hospitals to visit us and build a cooperation platform to achieve win-win development of medicine. In today's new competition and challenges in the pharmaceutical industry, we will have a broader pharmaceutical market. "Friends in the sea, the end of the world is like a neighbor", the company is willing to sincerely cooperate with all major orthopedic hospitals, chain pharmacies and friends from all walks of life to create brilliant!

本文链接: https://www.waitui.com/brand/8a4ae9536.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

天岳先进:2024年净利润1.8亿元 同比扭亏为盈

36氪获悉,天岳先进发布业绩快报,公司2024年实现营业收入17.68亿元,同比增长41.37%;实现归属于母公司所有者的净利润1.80亿元,同比扭亏为盈。主要原因是公司大尺寸、导电型产品产能产量持续提升,销售量增加,同时产品毛利率上升。

2小时前

小米集团卢伟冰:小米15 Ultra会是越级式的一代产品

36氪获悉,小米集团合伙人兼总裁、手机部总裁、小米品牌总经理卢伟冰发文称,小米手机未来5年高端化的目标之一,就是要在6000元+价格段实现规模化的突破,“Ultra是6K+突破的关键产品,而小米15 Ultra会是越级式的一代产品”。

2小时前

恒瑞医药:羟乙磺酸达尔西利片联合内分泌治疗乳腺癌III期临床试验达主要终点

36氪获悉,恒瑞医药公告称,公司自主研发的羟乙磺酸达尔西利片在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性女性乳腺癌辅助治疗的III期临床试验中,首次期中分析主要终点达到统计学显著性。研究结果显示,达尔西利联合内分泌治疗可显著降低患者复发风险,提高患者无侵袭性疾病生存期(IDFS)。公司已向国家药品监督管理局药品审评中心递交上市前沟通交流申请。该药品是公司自主研发的化学药品1类新药,是一种口服、高效、选择性的小分子CDK4/6抑制剂。

2小时前

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

2小时前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

本页详细列出关于海氏海诺的品牌信息,含品牌所属公司介绍,海氏海诺所处行业的品牌地位及优势。
咨询